803 results about "Eye drop" patented technology

The invention relates to eye drops containing exosomes and a preparation method and application thereof, and belongs to the technical field of eye drop preparation, the eye drops comprise exosome freeze-dried powder, the exosome freeze-dried powder is prepared from the exosomes obtained after mesenchymal stem cells are treated with TNF-alpha and IFN-alpha, and a herba houttuyniae extract, the eye drops provided by the invention can inhibit the phenotype of macrophage M1 and promote the M1 to be converted into the phenotype of M2; human corneal cell proliferation, migration and damage repair are promoted; mouse cornea injury repair is accelerated; the eye drops can be used for treating xerophthalmia, conjunctivitis and keratitis, and can also be used for preventing eye diseases and relieving asthenopia; the eye drops disclosed by the invention contain the exosome obtained after the mesenchymal stem cells are treated by the TNF-alpha and the IFN-alpha, so that the anti-inflammatory ability is stronger; the mesenchymal stem cell exosome and the herba houttuyniae extract are stored in a freeze-dried form, so that the activity is stable, and the storage time is long; in addition, the cordate houttuynia is cooperated with the exosome, so that the effect playing time can be prolonged, and the use frequency is reduced.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

The invention discloses carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops as well as a preparation method and application thereof, and relates to the technical field of eye drops and medical biogel. The carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops are prepared from tannic acid modified carboxymethyl chitosan and adipose tissue-derived stromal cell exosome freeze-dried powder, the carboxymethyl chitosan-hyaluronic acid-stem cell exosome eye drops provided by the invention can effectively treat xerophthalmia, and are stable in components, safe and reliable. The three components including the tannic acid modified carboxymethyl chitosan, the hyaluronic acid and the adipose tissue-derived stromal cell exosome coexist, so that the functions of all the components can be fully played, a synergistic effect is achieved, and a better treatment effect on xerophthalmia is achieved.

The present disclosure relates to a method of treating diabetic macular edema in a human subject in need thereof, said method comprising(i) an induction phase of topically administering to an affected eye of said subject, an eye drop formulation comprising 1.5% (w / v) dexamethasone, at a dosing of 5 to 7 drops a day for 3, 4, 5, 6 weeks, followed by,(ii) a maintenance phase of topically administering to an affected eye of said subject, said eye drop formulation comprising 1.5% (w / v) dexamethasone at a daily dosing less frequent than the induction phase for example 1-3 drops.

The invention discloses a liquid chromatography detection method and system for eye drops, and relates to the technical field of chromatographic detection.The liquid chromatography detection method comprises the steps that liquid chromatography analysis is conducted to obtain an original chromatographic signal; performing adaptive baseline correction on the original chromatographic signal to obtain a corrected chromatographic signal, synchronizing the corrected chromatographic signal to a chromatographic peak identification analysis model for identification to obtain a plurality of chromatographic peaks including principal component peaks and specific impurity peaks, and performing calculation to obtain a first integral area of the principal component peaks and a second integral area of the specific impurity peaks; the preset correction factor is combined with the first integral area and the second integral area to automatically carry out quantitative calculation on the eye drops, and a liquid chromatogram detection report of the eye drops is generated. The technical problems that in the prior art, main component peak and impurity peak recognition and quantification depend on manual processing in the eye drop liquid chromatogram detection process, and accuracy and consistency are insufficient are solved, and the technical effects that the accuracy and automation level of eye drop liquid chromatogram detection are improved, and it is guaranteed that main component and impurity quantification results are stable and consistent are achieved.

The invention relates to the technical field of biological medicine, in particular to eye drops containing recombinant protein as well as a preparation method and application of the eye drops. Comprising the following components: 0.01%-1% of recombinant human TFF3 protein, 0.1%-1% of an osmotic pressure regulator, 0.08%-2% of a pH regulator, 0.05%-0.15% of a thickening agent, 0.01%-0.1% of a surfactant, 0.01%-0.1% of a protective agent and the balance of water for injection, the traditional Chinese medicine composition can be used for treating the xerophthalmia, can promote wound healing and cell migration, has the effects of inhibiting inflammation and cell apoptosis, and can act on a plurality of target spots at the same time, so that the tear film stability is improved, ocular surface inflammation is inhibited, the vicious circle of the xerophthalmia is broken, and the xerophthalmia is treated more comprehensively and effectively; the problems that in the prior art, xerophthalmia medicine targets are single, and xerophthalmia cannot be comprehensively and effectively treated are solved.

The invention belongs to the technical field of microorganisms, and particularly relates to bifidobacterium animalis for relieving eye allergy and application of the bifidobacterium animalis. The invention provides an application of bifidobacterium animalis subsp. Lactis in preparation of a product for relieving eye allergy, the bifidobacterium animalis subsp. Lactis is Def +, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.35798. The Bifidobacterium animalis subsp. Lactis Def < + > provided by the invention can relieve the eye itching symptom, relieve red and swollen eyelids, reduce conjunctiva and cornea injury, relieve eye discomfort, relieve globular conjunctivitis cell infiltration, improve corneal epithelium thickening lesion, improve the anti-inflammatory ability and improve allergic conjunctivitis, keratitis and blepharitis marginata in a targeted manner. The eye drops are high in safety and resistant to gastrointestinal fluid, and a safe and long-acting scheme is provided for eye allergic diseases.

The invention discloses a preparation method of eye drops for treating glaucoma, cataract and vitreous opacification. The eye drops comprise the following components: berberine, N-acetyl carnosine and lycium barbarum polysaccharide. The specific formula comprises the following components: 0.1%-0.5% of berberine, 1%-3% of N-acetyl carnosine and 0.5%-2% of lycium barbarum polysaccharide. The invention belongs to the technical field of ophthalmic pharmaceutical preparations, and solves the problems that in the prior art, glaucoma, cataract and vitreous opacity generally need to be separately taken, the research on compound preparations is less, and the components possibly interact with one another.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention relates to the technical field of functional food, in particular to an eye-protecting and brain-strengthening composition as well as a preparation method and application thereof. The aronia, the astaxanthin, the DHA, the medlar, the hovenia dulcis thunb and the saffron crocus extract are compounded, various functional raw materials have a synergistic effect, the visual problem is improved through multiple channels, the cognitive ability is synchronously improved, and the astaxanthin eye drops have the effects of preventing retina oxidative damage, promoting eye blood circulation, relieving visual fatigue, protecting nerve cells and improving the cognitive state. Through reasonable proportioning, the composition for protecting eyes and strengthening brain has better effects of relieving visual discomfort, improving vision and improving brain health.

According to the nitrogen hydrochloride # imgabs0 # stine eye drops for treating allergic conjunctivitis and the preparation method of the nitrogen hydrochloride # imgabs0 # stine eye drops, the prepared eye drops can interact with the mucous layer on the surface of keratoconjunctiva by selecting specific solid lipid and a surfactant and controlling the dosage of the solid lipid and the surfactant; the retention capacity of the medicine in front of the cornea is prolonged, so that the medicine has good targeting property, the continuous release of the medicine is realized, the medication frequency can be reduced, the toxic and side effects of the medicine are reduced, the bioavailability is improved, the medication compliance of a patient is enhanced, and in the preparation and long-term storage processes, the medicine has better stability, and is suitable for popularization and application. Therefore, the problems of excessive drug due to multiple administration and poor stability of the active component nitrogen hydrochloride # imgabs1 # stine are solved.

The invention relates to the technical field of pharmaceutical preparations, and provides double-shell JAK inhibitor nanoparticles, a preparation method thereof and targeted delivery eye drops. The double-shell JAK inhibitor nanoparticle provided by the invention comprises a core, an inner shell and an outer shell, wherein the core comprises a nanostructure lipid carrier and a JAK inhibitor; the inner shell layer is a cationic polymer, and the outer shell layer is hyaluronic acid. Through the design of the positive charge inner shell layer and the negative charge outer shell layer, the dual functions of mucosa adhesion and active targeting are achieved, the surface of the nanoparticle is electronegative finally, cytotoxicity possibly caused by direct exposure of a cationic polymer is reduced, non-specific aggregation of the cationic polymer and electronegative protein in tears is avoided, and the stability of tears is improved. And the stability of the preparation is improved. The eye drops provided by the invention can obviously prolong the residence time of the JAK inhibitor on the ocular surface, enhance the cornea permeability, can actively target to ocular inflammatory cells, and have a wide application prospect.

The invention relates to a near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system and a preparation method and application thereof, a mesoporous silicon coated up-conversion nano-carrier and an efficient photosensitizer are compounded to form a photo-response core unit, and then the photo-response core unit is intelligently integrated with photo-curing hydrogel to form the near-infrared light response in-situ gelling and synergistic photo-thermal-photodynamic gel delivery system. The general problem of aggregation and quenching of photosensitive molecules is relieved by utilizing the unique space confinement effect of the mesoporous structure, the ICG photo-thermal efficiency and photodynamic performance are enhanced, under precise excitation of a near-infrared light source, the system can activate a photo-crosslinking reaction through an up-conversion luminescence process, in-situ conversion from a liquid eye drop preparation to a stable gel state is achieved, and the stability of the eye drop preparation is improved. A lasting drug reservoir is formed on the surface of the cornea; synchronously excited photodynamic and photo-thermal dual-mode treatment generates a remarkable synergistic antibacterial effect, and shows an excellent removal capability on pathogens including highly drug-resistant bacteria; meanwhile, an ideal microenvironment is created for tissue repair through high biocompatibility and a stable mechanical matrix, and integrity recovery of cornea structures and functions is promoted.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

The invention discloses eye drops containing L-ergothioneine and a preparation method of the eye drops. The eye drops are prepared from the following components in parts by weight: 0.0015 to 15 parts of L-ergothioneine, 0.001 to 0.01 part of a bacteriostatic agent, 0.05 to 15 parts of a buffering agent and the balance of normal saline, and the pH value of the eye drops is 5.0 to 7.0. Experiments show that L-ergothioneine can prevent and reverse denaturation of crystalline lens protein, the prepared eye drops containing L-ergothioneine can prevent and reduce opacity of crystalline lens protein, and the prevention and treatment effects on cataract are better than those of existing eye drops.

The invention belongs to the field of pharmaceutical preparations, and particularly relates to nitrogen hydrochloride # imgabs0 # stine eye drops and a preparation process thereof, the nitrogen hydrochloride # imgabs0 # stine eye drops comprise 0.05% of nitrogen hydrochloride # imgabs1 # stine, 0.2-0.3% of hydroxypropyl methylcellulose, 0.1-0.2% of edetate disodium, 0.12-0.15% of an isoosmotic adjusting agent, 0.04-0.07% of a preservative and 0.005-0.0075% of choline aromatic folic acid; the nitrogen hydrochloride # imgabs2 # stine eye drops prepared by the preparation method disclosed by the invention have the advantages that the adsorption of nitrogen hydrochloride # imgabs3 # stine on a low-density polyethylene bottle is well inhibited under the condition of visible light, and the reduction of the concentration of nitrogen hydrochloride # imgabs4 # stine in the eye drops is remarkably prevented, so that the medication safety is improved. Besides, the added cholinofolic acid and hydroxypropyl methylcellulose have small irritation to eyes under a specific ratio, and can also have a large enough contact angle with the eyes of rabbits at high temperature, so that the retention property of the eye drops on the eyes can be improved, and the drug effect can be favorably exerted.

The present invention relates to the technical field of eye drops, and specifically discloses a kind of wetting boric acid eye drops. The present invention also discloses a preparation method of the above-mentioned wetting boric acid eye drops, boric acid, chlorhexidine gluconate solution, and calcium disodium edetate are added to water, and stirred at 60-70°C to obtain a boric acid complex; sodium hyaluronate and sodium alginate are added to water and stirred, and hypromellose is added, and stirred at 30-40°C to obtain a hypromellose complex; soy lecithin, cholesterol, and ethylparaben are added to chloroform and stirred to obtain phase A; collagen and carboxymethyl chitosan are added to citric acid aqueous solution and stirred to obtain phase B; phase A is added to phase B under stirring, ultrasonic treatment, 50-60°C vacuum rotary evaporation to remove chloroform, citric acid aqueous solution is added for hydration, ultrasonic treatment, and filtration to obtain liposomes; boric acid complex, hypromellose complex, and liposomes are mixed evenly, and the pH value of the adjustment system is 6.5-7.5.

The invention relates to an information distribution marketing ecosystem connecting eyewear, eyewear accessories, signs, stickers to present prescriptions, information or telemedicine connection capabilities based on NFC technology embedded or adapted onto products. The method and system comprising of using mobile applications to program eyeglasses or contact lenses prescriptions, weblink connection, product information, synergistic marketing, appointment scheduling links, and / or virtual audio telemedicine direct links into an NFC tag to one or more products such as signs, stickers, eyewear frames, eyewear accessories. NFC embedded products can be used in pharmacies, medical offices, optical retailer shops, department stores, or eye doctors' offices. The NFC tag on selected products and their parts helps to enable a user to use an NFC smartphone to touch the NFC tag, to reach information via centralized connection and / or decentralized connection using the internet.

The invention belongs to the technical field of pharmaceutical analysis, and particularly relates to a method for detecting the content of carbomer in eye drops. The method comprises the following steps: by adopting a two-time washing and centrifugal separation mode, controlling the washing and centrifugal times, centrifugal conditions and washing volume, separating carbomer and brinzolamide from other auxiliary materials in the brinzolamide eye drops, obtaining the weights of carbomer and brinzolamide by adopting a drying and weighing mode, subtracting the weight of brinzolamide, and calculating the content of the auxiliary materials in the brinzolamide eye drops. And calculating to obtain the carbomer content in the sample. The method is suitable for detecting the carbomer content in the carbomer-containing brinzolamide eye drops, and is simple and convenient to operate, efficient, accurate and low in cost.

An eye drop propulsion device and method for propelling a drop of fluid towards an eye, including a compression chamber connected to a container configured to retain fluid, a dispenser aperture connected to the compression chamber and configured to be selectively occluded or not occluded, and a compressor configured to alter pressure in the compression chamber such that when the compressor is activated when the dispenser aperture is occluded, air is forced to flow from the compression chamber into the container, and when the compressor is deactivated, a vacuum is created in the compression chamber causing a portion of fluid in the container to flow into the compression chamber, and when the compressor is activated when the dispenser aperture is not occluded, a drop of fluid is propelled towards the eye.

The utility model discloses an anti-pollution eyedrop bottle with a positioning support. The anti-pollution eyedrop bottle comprises an anti-pollution eyedrop bottle body and the positioning support. The anti-pollution eyedrop bottle body is divided into a liquid storage area and a liquid outlet area according to the structure; the liquid storage area is cylindrical, the bottom of the liquid storage area is connected with the liquid outlet area, the liquid outlet area is conical, and a liquid outlet is formed in the bottom of the liquid outlet area; a blocking assembly and a quantifying assembly are further arranged in the anti-pollution eyedrop bottle body, the blocking assembly is used for limiting one-way circulation of liquid at the liquid outlet, and the quantifying assembly is used for ensuring constant liquid outlet every time; the outer surface of the bottom of the liquid storage area is sleeved with the positioning support, and the bottom face of the positioning support is located in the axis direction of the anti-pollution eye drop bottle body and is lower than the liquid outlet; and an isolation layer is further arranged on the outer surface of the liquid outlet and used for being isolated from the external environment. By using the device, the operation can be easily carried out, and drug use errors are avoided. Meanwhile, the sealing performance of the eyedrops in the using process is guaranteed, and pollution is reduced.

The invention relates to a pharmaceutical composition for an eye drop dosage form. The pharmaceutical composition comprises a lipid, white soft paraffin and liquid paraffin. Each gram of the ophthalmic pharmaceutical composition comprises 3 to 500 milligrams of lipid, 100 to 250 milligrams of white soft paraffin and 1 to 797 milligrams of liquid paraffin.

The invention relates to an exosome composition, application thereof and exosome eye drops, and relates to the technical field of pharmaceutical preparations, and the exosome composition is composed of a mesenchymal stem cell exosome and a rabdosia lingua extract in a weight ratio of (5-10): (13-21). The exosome composition is composed of the mesenchymal stem cell exosome and the rabdosia lophanthoides extract in a proper proportion, and the mesenchymal stem cell exosome and the rabdosia lophanthoides extract are matched for use, so that the exosome composition has an excellent treatment effect on cataract and can be applied to preparation of products such as eye drops and the like, and a new treatment means is provided for cataract patients. In addition, the exosome eye drops provided by the invention do not contain side-effect components such as preservatives and hormones, have no obvious irritation and can be used for a long time.

The invention belongs to the technical field of biological medicines, and particularly relates to a dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle as well as a preparation method and application of the dual-cell-penetrating peptide modified STING inhibitor-containing specific vascular endothelium targeting nanoparticle. The STING inhibitor is wrapped in the lipidosome to obtain the lipidosome nano-drug, and the lipidosome is used as a drug carrier, so that the water solubility and bioavailability of the lipidosome nano-drug can be improved; meanwhile, the cell-penetrating peptide and the targeted cell-penetrating peptide are used for jointly modifying the liposome nano-drug, and the cell-penetrating peptide and the targeted cell-penetrating peptide synergistically improve the cell-penetrating performance, help the drug to penetrate through an eye barrier and target retinal vascular endothelial cells, and increase the bioavailability of the drug. Moreover, the obtained nanoparticles exist in a liquid form and can be directly used as eye drops for treating eyes with retinopathy, so that a convenient and non-invasive eye disease treatment mode can better benefit patients with retinopathy, reduce retinal angiogenesis of the patients and facilitate treatment and prognosis of diseases.

The invention discloses traditional Chinese medicine suspension eye drops and a preparation method thereof, and the traditional Chinese medicine suspension eye drops are prepared from the following raw materials in parts by weight: 1-3 parts of a traditional Chinese medicine composition, 4-7 parts of hydroxypropyl-beta-cyclodextrin, 0.5-2 parts of microcrystalline cellulose-sodium carboxymethyl cellulose and auxiliary materials. The traditional Chinese medicine suspension eye drops provided by the invention abandon a traditional eye ointment form, are directly dropped for use, are convenient to use, have good stability and dispersity, and are excellent in use curative effect and medication experience; on the basis of keeping the clinical efficacy of the Marcher eight-treasure ancient prescription, secondary development and research are scientifically carried out, so that the Marcher eight-treasure ancient prescription plays a greater clinical treatment role, and has a wider market development prospect.

The invention discloses a cassia seed antibacterial liquid for eyes and a preparation method thereof. The semen cassiae antibacterial liquid for the eyes is prepared from the following components in percentage by mass: 2.0 to 3.0 percent of semen cassiae extract, 2.0 to 3.0 percent of magnolia flower leaf extract, 2.0 to 3.0 percent of flos chrysanthemi indici extract, 2.0 to 3.0 percent of radix gentianae extract, 2.0 to 3.0 percent of flos eriocauli extract, 1.0 to 2.0 percent of radix ginseng extract, 2.0 to 3.0 percent of rhizoma polygonati extract, 1.0 to 2.0 percent of radix codonopsis extract and the balance of water. The traditional Chinese medicine composition has the beneficial effects that various eyesight-improving traditional Chinese medicine components are adopted, the traditional Chinese medicine composition does not contain any artificial hormone and antibiotic, has no toxic or side effect, has the effects of clearing liver and improving eyesight, resisting bacteria and inflammation, and improving retina microcirculation and blood flow volume, and is matched with chlorhexidine acetate, so that the traditional Chinese medicine composition has the effects of clearing liver and improving eyesight, resisting bacteria and inflammation, and improving retina microcirculation and blood flow volume. The eye drops have the advantages that the eye drops have strong inhibition effects on candida albicans, escherichia coli and staphylococcus aureus, the components of the eye drops do not contain any irritant component, irritation influence on eyes is avoided, the preparation method is simple, and the eye drops can be easily applied to large-scale production and processing processes.

The invention provides pet tear stain eye drops containing haematococcus pluvialis extract, the pH value of the eye drops is 6.8-7.2, the osmotic pressure is 280-320 mOsm / kg, the viscosity is 3-8 mPa.s (25 DEG C), and the eye drops comprise the following components in percentage by mass: 0.05-0.5% of haematococcus pluvialis astaxanthin extract (based on the astaxanthin content being greater than or equal to 5%), 0.05-0.5% of a pH regulator (based on the astaxanthin content being greater than or equal to 5%), and the balance of water. 1%-3% of an anti-inflammatory plant compound; 0.5%-1.2% of an isoosmotic adjusting agent; 0.2%-0.8% of a nano carrier stabilizer; 0.01%-0.1% of a pH buffer agent; compared with the prior art, the invention has the following beneficial effects: the corneal permeability of the astaxanthin is increased to 82% (measured by a Franz diffusion cell) through PLGA coating, and is increased by 5.5 times compared with the corneal permeability of the astaxanthin in a free state (15%); natural tocopherol is reserved through supercritical CO2 extraction (the content of the natural tocopherol is larger than or equal to 0.5% through HPLC detection), and the retention rate of the astaxanthin stored at 40 DEG C for 90 days is larger than or equal to 90% through Calendula quercitrin inhibits the expression of IL-6 (enzyme-linked immunosorbent assay (ELISA) detection is reduced by 76%), and chamomile bisabolol blocks a COX-2 pathway.

The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug / cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 μm.

An eye drop propulsion device and method for propelling a drop of fluid towards an eye includes a compression chamber, a container configured to communicate fluid into the compression chamber, an occludable dispenser aperture, and a compressor configured to alter pressure in the compression chamber such that when the compressor is activated and the dispenser aperture is not occluded, a drop of fluid is propelled towards the eye, and when the compressor is deactivated and the dispenser aperture is occluded, a vacuum is created in the compression chamber causing fluid to flow into the compression chamber. Alternatively, the device includes a dispenser aperture connected to the compression chamber and configured to allow at least a drop to be added to the compression chamber from the container without fluid exiting the dispenser aperture, and to allow a drop of fluid to be propelled towards the eye when the compressor is activated.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to emedastine fumarate eye drops and a preparation method thereof. The invention provides emedastine fumarate eye drops, the pH value of the emedastine fumarate eye drops is 7.2-7.6, and the emedastine fumarate eye drops are prepared from the following components in parts by weight: 0.84-0.92 part of emedastine fumarate, 2-3 parts of a thickening agent, 4.5-5.5 parts of a buffering agent, 6-8 parts of an osmotic pressure regulator, a pH regulator and 950-1050 parts of water, wherein the thickening agent is hydroxypropyl methylcellulose 2910. According to the emedastine fumarate eye drops disclosed by the invention, the hydroxypropyl methylcellulose 2910 is used as a thickening agent, so that the obtained emedastine fumarate eye drops are more clear, less in impurity content and higher in stability; meanwhile, a specific preparation method is limited, the dissolution time of the osmotic pressure regulator is greatly shortened, and the production efficiency is improved.